BadgerCare Plus and Medicaid SSI ProgramsJune 9, 2023
Clinical Criteria updates for December 2022
On May 20, 2022, August 19, 2022, September 12, 2022, November 18, 2022, December 12, 2022, and January 12, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Document number | Clinical Criteria title | New or revised |
July 12, 2023 | *CC-0226 | Elahere (mirvetuximab) | New |
July 12, 2023 | *CC-0227 | Briumvi (ublituximab) | New |
July 12, 2023 | *CC-0228 | Leqembi (lecanemab) | New |
July 12, 2023 | *CC-0229 | Sunlenca (lenacapavir) | New |
July 12, 2023 | CC-0029 | Dupixent (dupilumab) | Revised |
July 12, 2023 | CC-0185 | Oxlumo (lumasiran) | Revised |
July 12, 2023 | *CC-0072 | Selective Vascular Endothelial Growth Factor (VEGF) Inhibitors | Revised |
July 12, 2023 | CC-0130 | Imfinzi (durvalumab) | Revised |
July 12, 2023 | CC-0223 | Imjudo (tremelimumab-actl) | Revised |
July 12, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised |
July 12, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised |
July 12, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised |
July 12, 2023 | *CC-0107 | Bevacizumab for Non-ophthalmologic Indications | Revised |
July 12, 2023 | *CC-0166 | Trastuzumab Agents | Revised |
July 12, 2023 | *CC-0182 | Iron Agents | Revised |
July 12, 2023 | *CC-0002 | Colony Stimulating Factor Agents | Revised |
July 12, 2023 | *CC-0075 | Rituximab agents for Non-Oncologic Indications | Revised |
July 12, 2023 | *CC-0001 | Erythropoiesis Stimulating Agents | Revised |
July 12, 2023 | *CC-0062 | Tumor Necrosis Factor Antagonists | Revised |
July 12, 2023 | *CC-0167 | Rituximab Agents for Oncologic Indications | Revised |
WIBCBS-CD-020016-23-CPN19724
PUBLICATIONS: July 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone